In addition, Morris et al reported that using PSA levels, bone scintigraphy and soft tissue imaging as references, FDG-PET might be a promising outcome measure after chemotherapy in prostate cancer [10]. This evidence concerns the gene KLK3 and Familial prostate cancer.